Zobrazeno 1 - 10
of 31
pro vyhledávání: '"35"'
Autor:
Kohei Shitara, Akihiro Sato, Toshihiko Doi, Tomohiro Nishina, Kei Muro, Shunji Takahashi, Atsushi Ohtsu, Shogo Nomura, Hideaki Bando, Kensei Yamaguchi, Hirofumi Kuno, Hirofumi Yasui
Publikováno v:
European Journal of Cancer. 62:46-53
Aim American phase I studies have reported that the recommended dose of TAS-102 (trifluridine/tipiracil) was 25 mg/m 2 twice a day (b.i.d.), although this schedule did not provide clinically relevant improvements in a phase II study of advanced gastr
Publikováno v:
European Journal of Cancer. 43:1171-1179
Background The aim of United Kingdom Children’s Cancer Study Group (UKCCSG) HD82 was to establish the efficacy of chlorambucil/vinblastine/procarbazine/prednisolone (ChlVPP) in the treatment of childhood Hodgkin’s lymphoma stages II–IV and radi
Autor:
Jean-Christophe Sabourin, T. de Baere, T. Aparicio, Emmanuel Mitry, Eric Baudin, Ph. Rougier, Michel Ducreux, Martin Schlumberger
Publikováno v:
European Journal of Cancer. 37:1014-1019
A few studies have suggested an antitumour activity of somatostatin analogues in neuroendocrine tumours (NET). The aim of this study was to evaluate the antitumour efficacy of somatostatin analogues in patients with documented progressive tumours. 35
Publikováno v:
European Journal of Cancer. 34:659-663
In this phase II study, paclitaxel was added to the combination of cisplatin and etoposide (TPE regimen), in 37 patients with advanced non-small cell lung cancer, using a multifractionated dosing schedule. The total dose of paclitaxel (175-200 mg/m2)
Publikováno v:
European Journal of Cancer. 31:S188-S189
38 pts with primary GCT of the testis (35) or the CNS (3) received methotrexate (M) 250 mg/m2 as a 24 h infusion with fol. acid d.l, cisplatin (P) 100 mg/m2 dA, etoposide (V) 100 mg/m2 d. 4–6 and ifosfamide (I) 5 g/m2 d.5 with mesna (MVIP). Of thos
Autor:
Hilary Thomas, P. Bougnoux, Willem M. Smit, Danny Rischin, H. Cure, R.J. Atkinson, Philip Beale, L. Dirix, Martin Gore
Publikováno v:
European Journal of Cancer. 38:S7-S12
Results of ZD0473 in platinum-pretreated ovarian cancer: analysis according to platinum free interval. Resistance to platinum-containing regimens can develop in many women, with ovarian cancer and may lead to relapse in > 80% of patients. ZD0473 is a
Autor:
Martin Gore, H. Cure, Willem M. Smit, Danny Rischin, P. Bougnoux, Philip Beale, Hilary Thomas, R.J. Atkinson, L. Dirix
Publikováno v:
European Journal of Cancer. 38:2416-2420
A phase II trial of ZD0473 in platinum-pretreated ovarian cancer. The primary aim of this phase 11 trial was to assess the antitumour activity of ZD0473 in ovarian cancer patients who had failed initial platinum-based therapy. Patients (n = 94) were
Autor:
Jantien Wanders, K. Kroon, B.P. Schöffski, Pierre Fumoleau, Jan H.M. Schellens, Alain Ravaud, Axel Hanauske, L. Geoffrois, Markus Borner
Publikováno v:
European Journal of Cancer. 37:1642-1647
A phase II study was performed to evaluate 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil (UFT) and leucovorin as first-line chemotherapy in European patients with advanced gastric cancer. From 38 patients, 25 were evaluable for response and 36 for
Autor:
Gonzalo Recondo, Elizabeth Mickiewicz, F. Pujol, M. Vilanova, M. Montiel, A. Zori Comba, Luis Balbiani, C. Blajman, A. Schmilovich, Eduardo Richardet, E. Cazap, F. Lastiri, J. Simon, E. Wasserman, S. Bella, M. Chacon, M. Van Kooten, F. Coppola, R. Giglio, Jeannette Rodger, F. Perazzo
Publikováno v:
European Journal of Cancer. 37:1006-1013
The aim of this study was to examine the efficacy and safety of both oxaliplatin as a single agent and oxaliplatin in combination with daily×5 bolus 5-fluorouracil and folinic acid (5-FU/FA, Mayo clinic regimen) in the first-line treatment of metast
Autor:
K.P Lynch, Robert Steele, P. D. Brown, H Kasem, Gillian Tierney, Simon L. Parsons, A.W Millar, J.T Lury, R C Stuart, N.R. Griffin
Publikováno v:
European Journal of Cancer. 35:563-568
The aim of this study was to evaluate the safety and tolerability of 4 weeks administration of marimastat, and to seek evidence of biological activity as observed by changes in the endoscopic appearance of the gastric tumours. 35 patients with advanc